Peter Pfreundschuh
Keine laufenden Positionen mehr
Vermögen: 1 Mio $ am 31.05.2024
Profil
Peter P.
Pfreundschuh is currently the Director at Gitbasic LLC and the Director at Speratus Therapeutics, Inc. Previously, he worked as the Executive Director-Business Development at AstraZeneca Pharmaceuticals LP from 2007 to 2008.
He also served as the Director at Reproductive Medicine Associates of New Jersey and Principal at American Standard Cos., Inc. From 2013 to 2016, he held the position of Chief Financial Officer & Executive VP-Finance at Immunomedics, Inc. Prior to that, he worked as a Principal at Johnson & Johnson from 1999 to 2007.
He has also worked as an Auditor at Ernst & Young LLP and as the Chief Financial Officer & Treasurer at 3-Dimensional Pharmaceuticals, Inc. From 2008 to 2013, he served as the Chief Financial Officer at CircuLite, Inc. In 2017 and 2018, he held the position of Chief Financial Officer at Sucampo Pharmaceuticals LLC.
He was also a Principal at Alimenterics, Inc. From 2018 to 2020, he served as the Chief Financial & Compliance Officer, Secretary at UroGen Pharma Ltd.
From 2020 to 2022, he held the position of Chief Financial Officer at Frequency Therapeutics, Inc. Currently, he is the Chief Financial & Accounting Officer at Voyager Therapeutics, Inc. Mr. Pfreundschuh obtained an MBA from Rider University in 2002 and an undergraduate degree from Rutgers Business School in 1991.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 21.02.2024 | 175 669 ( 0,32% ) | 1 Mio $ | 31.05.2024 |
Aktive Positionen von Peter Pfreundschuh
| Unternehmen | Position | Beginn |
|---|
Ehemalige bekannte Positionen von Peter Pfreundschuh
| Unternehmen | Position | Ende |
|---|---|---|
| VOYAGER THERAPEUTICS, INC. | Finanzdirektor/CFO | 04.05.2024 |
| KORRO BIO, INC. | Finanzdirektor/CFO | 31.03.2022 |
| UROGEN PHARMA LTD. | Finanzdirektor/CFO | 01.10.2020 |
| SUCAMPO PHARMACEUTICALS, INC. | Finanzdirektor/CFO | 01.02.2018 |
| IMMUNOMEDICS, INC. | Finanzdirektor/CFO | 01.09.2016 |
Ausbildung von Peter Pfreundschuh
| Rider University | Masters Business Admin |
| Rutgers Business School | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| JOHNSON & JOHNSON | Health Technology |
| UROGEN PHARMA LTD. | Health Technology |
| VOYAGER THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 8 |
|---|---|
| American Standard Cos., Inc. | Producer Manufacturing |
Immunomedics, Inc.
 Immunomedics, Inc. BiotechnologyHealth Technology Immunomedics, Inc. researching, developing, manufacturing, and marketing biopharmaceutical products. It focuses on monoclonal antibody-based products for the targeted treatment of cancer. The company was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ. | Health Technology |
Ernst & Young LLP
 Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Commercial Services |
CircuLite, Inc.
 CircuLite, Inc. Medical DistributorsDistribution Services CircuLite, Inc. provided treatment for heart disorders. The company was founded by Paul J. Southworth and Paul Spence in November 2004 and was headquartered in Teaneck, NJ. | Distribution Services |
AstraZeneca Pharmaceuticals LP
 AstraZeneca Pharmaceuticals LP Pharmaceuticals: MajorHealth Technology AstraZeneca Pharmaceuticals LP develops, manufactures and markets prescription pharmaceutical drugs. It sells products related to gastrointestinal, cardiovascular, neuroscience, respiratory and oncology infections. The company was founded in 1953 and is headquartered in Wilmington, DE. | Health Technology |
Sucampo Pharmaceuticals, Inc.
 Sucampo Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the development, identification, acquisition, and delivery of innovative pharmaceutical products. The company was founded by Ryuji Ueno and Sachiko Kuno on December 5, 1996 and is headquartered in Bethesda, MD. | Health Technology |
3-Dimensional Pharmaceuticals, Inc.
 3-Dimensional Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology 3-Dimensional Pharmaceuticals, Inc. was acquired by Johnson & Johnson. 3-Dimensional Pharmaceuticals, Inc. operates as a drug discovery and development company that has a pipeline of drug candidates in the areas of cancer and inflammation, and metabolic and cardiovascular diseases | Health Technology |
Frequency Therapeutics, Inc.
 Frequency Therapeutics, Inc. BiotechnologyHealth Technology Frequency Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the business of developing therapeutics to activate a person's innate regenerative potential to restore function. The firm is also involved in creating and commercializing therapeutics to potentially transform the lives of individuals by repairing or reversing damage done to cells, tissue, and organs. The company was founded by Robert S. Langer, David L. Lucchino, Christopher R. Loosey, and Will J. McLean on November 13, 2014 and is headquartered in Lexington, MA. | Health Technology |
